IPCALAB
IPCA Laboratories Limited (IPCALAB) Stock Analysis
IPCA Laboratories Limited manufactures pharmaceutical formulations and APIs across therapeutic areas for India and exports. It has strong brands in anti-malarials, diabetes, and cardiovascular therapies. The company operates multiple plants with global approvals. It is a respected listed pharma major.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,832.60
-4.32% 1W | +48.60% 52W
Market Cap
46.5k CR
P/E Ratio
35.5
52W High
₹2038
52W Low
₹1251.6
Div. Yield
0.31%
Beta
0
50 DMA
₹1918.3
200 DMA
₹1658.7
Profit Margin
12.9%
Inst. Own.
45.7%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,585 | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 | 2,392 | 2,388 | 2,788 |
| Expenses | 1,278 | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 | 1,859 | 1,905 | 2,119 |
| Operating Profit | 308 | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 | 545 | 533 | 484 | 670 |
| OPM % | 19% | 18% | 16% | 16% | 19% | 19% | 21% | 19% | 18% | 21% | 22% | 20% | 24% |
| Other Income | 45 | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 | -30 | 38 | 48 | 25 |
| Interest | 31 | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 | 20 | 18 | 20 | 12 |
| Depreciation | 69 | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 | 103 | 108 | 107 | 111 |
| Profit before tax | 252 | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 | 392 | 446 | 404 | 572 |
| Tax % | 34% | 39% | 23% | 96% | 31% | 29% | 25% | 49% | 29% | 28% | 18% | 24% | 26% |
| Net Profit | 164 | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 | 281 | 364 | 307 | 424 |
| EPS in Rs | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 11.79 | 15.84 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,599 | 10,126 |
| Expenses | 2,604 | 2,573 | 2,705 | 2,803 | 3,051 | 3,715 | 3,843 | 4,472 | 5,272 | 6,338 | 7,166 | 7,609 | 7,894 |
| Operating Profit | 541 | 294 | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,990 | 2,232 |
| OPM % | 17% | 10% | 14% | 14% | 19% | 20% | 29% | 23% | 15% | 17% | 19% | 21% | 22% |
| Other Income | 32 | 21 | 11 | 41 | 56 | 65 | 59 | 54 | 123 | 17 | -114 | 80 | 81 |
| Interest | 32 | 35 | 27 | 28 | 22 | 20 | 12 | 11 | 48 | 141 | 88 | 79 | 69 |
| Depreciation | 180 | 163 | 173 | 178 | 182 | 210 | 209 | 232 | 262 | 357 | 398 | 418 | 429 |
| Profit before tax | 361 | 117 | 262 | 291 | 546 | 739 | 1,389 | 1,136 | 745 | 843 | 1,131 | 1,573 | 1,814 |
| Tax % | 28% | 18% | 26% | 18% | 19% | 18% | 17% | 20% | 34% | 37% | 30% | 24% | |
| Net Profit | 254 | 93 | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 1,184 | 1,375 |
| EPS in Rs | 10.07 | 3.69 | 7.71 | 9.49 | 17.60 | 23.99 | 44.94 | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 | 51.63 |
| Dividend Payout % | 5% | -0% | 6% | 5% | 9% | 10% | 9% | 11% | 22% | 19% | 14% | -0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 16.0% | 12.0% | 13.0% |
| Profit CAGR | 37.0% | 1.0% | 30.0% |
Shareholding Pattern
Promoters44.72%
FIIs10.42%
DIIs36.45%
Public8.09%
Promoters44.72%
FIIs10.62%
DIIs36.99%
Public7.33%
Promoters44.72%
FIIs10.63%
DIIs37.13%
Public7.21%
Promoters44.72%
FIIs10.72%
DIIs37.04%
Public7.19%
Promoters44.72%
FIIs11.53%
DIIs36.60%
Public7.15%
Promoters46.29%
FIIs10.58%
DIIs33.74%
Public9.06%
Promoters46.30%
FIIs10.51%
DIIs34.05%
Public8.82%
Promoters44.72%
FIIs10.75%
DIIs35.73%
Public8.45%
Promoters44.72%
FIIs10.63%
DIIs37.13%
Public7.21%
Promoters44.72%
FIIs11.53%
DIIs36.60%
Public7.15%
IPCALAB
Holdings Analysis
Key strengths & risk signals
78
Overall
85
Fundamental
71
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.31% yield - little to no income.
RECOVERY MODE! Current price (1832.6) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.3% (1 week), 6.0% (1 month), 3.6% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1918.3) is above 200-day average (1658.7) - positive signal.
GOOD YEAR! Stock gained 48.6% in the last year.
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 285,820 vs down days: 199,560. Ratio: 1.43x
Fundamental & Technical Analysis
78Overall
85Fundamental
71Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 15.5% (VERY GOOD, 13/15). Profit CAGR: 34.3% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 12.9% profit margin - acceptable profitability.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.03 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.31% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 8.46% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1918.3) is above 200-day average (1658.7) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (1832.6) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
GOOD YEAR! Stock gained 48.6% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 285,820 vs down days: 199,560. Ratio: 1.43x
RSI
4/5
APPROACHING OVERSOLD! RSI at 33.8 - watch for reversal.
52W Range
4/5
UPPER HALF! Trading at 73.9% of 52W range - positive territory.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.3% (1 week), 6.0% (1 month), 3.6% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
IPCALAB
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-06-04 | Concall PDF | |
| Q3FY262026-02-18 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPCALAB | ₹1,832.60 | 35.5 | 12.9% | 15.5% | 34.3% | +48.6% | 78 | BREAKDOWN | +72.3% | +34.4% | +20.8% | +16.7% |
| GLAND | ₹3,043.40 | 44.4 | 16.8% | 21.3% | 9.6% | +59.2% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
| AJANTPHARM | ₹3,329.00 | 36.7 | 19.6% | 13.4% | 21.6% | +37.8% | 82 | BOUNCE FROM SUPPORT | +30.9% | +25.3% | +24.8% | +14.4% |
| ABBOTINDIA | ₹26,170.00 | 34.4 | 23.1% | 9.0% | 17.8% | -11.8% | 69 | APPROACHING RESISTANCE | +17.1% | +8.5% | +4.3% | +6.1% |
| EMCURE | ₹1,820.60 | 34.1 | 10.4% | 15.4% | 20.2% | +36.3% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| ALKEM | ₹5,050.00 | 28 | 14.3% | 8.3% | 32.7% | -8.3% | 67 | APPROACHING SUPPORT | -21.7% | +119.9% | +10.9% | +3.8% |
| WOCKPHARMA | ₹1,954.90 | 77.5 | 11.2% | 7.8% | – | +46.4% | 58 | BREAKDOWN | -217.8% | -36.1% | +25.9% | -3.7% |
| GLENMARK | ₹2,226.70 | 35 | 10.1% | 13.5% | 66.1% | +20.9% | 70 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
Data from TradeAlone · Updated daily
IPCALAB News
IPCA Laboratories Limited (NSE: IPCALAB) extends gains, moves up 10% intraday2026-08-17IPCA Laboratories Limited (IPCALAB) extends gains by 7% intraday2026-08-17IPCA Laboratories Limited (IPCALAB) edges up 6% intraday near resistance2026-08-13IPCA Laboratories Limited (NSE: IPCALAB) clears resistance, moves up 5% intraday2026-06-30Ipca Laboratories Limited (ipcalab) and Bhami’s Research Laboratory Announce Global Licensing Collaboration2026-06-12
